Recurrence rate of hepatocellular carcinoma in patients with hepatocellular carcinoma and compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: A Romanian national cohort study

Trial Profile

Recurrence rate of hepatocellular carcinoma in patients with hepatocellular carcinoma and compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: A Romanian national cohort study

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2017 New trial record
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top